ASH1L and hepatocellular carcinoma: Further analysis of data from 1380 HCC patients across 5 studies in cBioPortal [33] revealed that 6% of patients exhibited ASH1L-AS1 amplification and structural variations (Fig. S2A), suggesting that its upregulation may involve other unrevealing mechanisms.